Comparison of Efficacy and Postoperative Complications of Lauromacrogol Foam Sclerosant and Lauromacrogol Injection in Patients with Internal Hemorrhoids
-
摘要:
目的 探讨内痔患者中聚桂醇泡沫硬化剂与聚桂醇注射液的疗效对比。 方法 随机选取2020年2月至2021年8月昆明市第二人民医院治疗的94例内痔患者,采用数字表法分为研究组和对照组。对照组(n = 47)采用聚桂醇注射液治疗,研究组(n = 47)采用聚桂醇泡沫硬化剂治疗,记录2组治疗总有效率、临床指标(总疗程、手术费用、聚桂醇用量)、术中局部出血、术后疼痛以及并发症发生情况。 结果 研究组总有效率高于对照组,差异有统计学意义(P < 0.05);研究组总疗程天数、手术费用和聚桂醇用量均比对照组低,差异有统计学意义( P < 0.05);研究组术中局部出血量低于对照组,术后疼痛程度低于对照组,差异有统计学意义( P < 0.05);研究组并发症发生率比对照组低,差异有统计学意义( P < 0.05)。 结论 对内痔患者采用聚桂醇泡沫硬化剂的治疗效果优于聚桂醇注射液,并且可缩短患者住院时间、减少其聚桂醇用量,住院费用、并发症发生率降低,值得推广应用。 Abstract:Objective To investigate the efficacy of lauromacrogol foam sclerosant and lauromacrogol injection in patients with internal hemorrhoids. Methods A total of 94 patients with internal hemorrhoids treated in Kunming Second People’s Hospital from February 2020 to August 2021 were randomly selected and divided into study group and control group by number table method. The control group (n = 47)was treated with lauromacrogol injection, and the study group (n = 47)was treated with lauromacrogol foam sclerosant. The total effective rate, clinical indicators (total course of treatment, operation cost, dosage of lauromacrogol ), intraoperative bleeding, postoperative pain and complications. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P < 0.05). The total duration of treatment, operation cost and dosage of lauromacrogol in the study group were lower than those in the control group, and the differences were statistically significant ( P < 0.05). The intraoperative local blood loss and postoperative pain in the study group were lower than those in the control group, and the differences were statistically significant ( P < 0.05). The incidence of complications in the study group was lower than that in the control group, and the difference was statistically significant ( P < 0.05). Conclusion Lauromacrogol foam sclerosant is better than lauromacrogol injection in the treatment of patients with internal hemorrhoids, and can shorten the length of hospital stay, reduce the dosage of lauromacrogol, hospitalization costs, complications, and is worthy of promotion and application. -
Key words:
- Internal hemorrhoids /
- Lauromacrogol foam sclerosant /
- Clinical efficacy /
- Bleeding /
- Complications
-
表 1 2组患者一般资料比较[( $\bar x \pm s $),n(%)]
Table 1. Comparison of general data between the two groups [( $\bar x \pm s $),n(%)]
组别 n 性别(男/女) 年龄(岁) 疾病分型 Ⅰ度 Ⅱ度 Ⅲ度 对照组 47 42/5 41.3 ± 3.1 26(55.3) 14(29.8) 7(14.9) 研究组 47 40/7 41.1 ± 3.0 24(51.1) 15(31.9) 8(17.0) t/χ2 - 1.906 1.748 1.368 P - 0.102 0.067 0.211 表 2 2组临床治疗总有效率比较[n(%)]
Table 2. Comparison of total effective rate between the two groups [n(%)]
组别 n 治愈 有效 无效 总有效率 对照组 47 23(48.9) 15(31.9) 9(19.1) 38(80.9) 研究组 47 29(61.7) 17(36.2) 1(2.1) 46(97.9) χ2 - - - - 5.101 P - - - - 0.015* *P < 0.05。 表 3 2组临床指标比较( $\bar x \pm s $)
Table 3. Comparison of clinical indicators between the two groups ( $\bar x \pm s $)
组别 n 总疗程(d) 手术费用(元) 聚桂醇用量(mL) 对照组 47 4.1 ± 0.7 2832.1 ± 47.37.5 ± 1.1 研究组 47 2.6 ± 0.5 2510.9 ± 13.74 ± 0.3 t - 10.695 16.857 12.511 P - 0.047* 0.032* 0.040* *P < 0.05。 表 4 2组出血及疼痛情况比较[n(%)]
Table 4. Comparison of bleeding and pain between the two groups [n(%)]
组别 n 术中局部出血 术后疼痛 无 轻度 显著 无 轻度 显著 对照组 47 29(61.7) 9(19.1) 9(19.1) 40(85.1) 5(10.6) 2(4.2) 研究组 47 38(80.9) 6(12.8) 3(6.4) 45(95.7) 1(2.1) 1(2.1) Z - 4.958 5.063 P - 0.037* 0.025* *P < 0.05。 表 5 2组并发症情况比较[n(%)]
Table 5. Comparison of complications between the two groups [n(%)]
组别 n 异位栓塞 肛周感染 肛门狭窄 总发生率 对照组 47 0(0.0) 4(8.5) 1(2.1) 5(10.6) 研究组 47 0(0.0) 1(2.1) 0(0.0) 1(2.1) χ2 - - 4.139 1.069 4.857 P - - 0.047* 0.124 0.022* *P < 0.05。 -
[1] Abe T,Kunimoto M,Hachiro Y,et al. Long-term outcomes of aluminum potassium sulfate and tannic acid sclerotherapy for prolapsed hemorrhoids:A single-center,observational study[J]. Diseases of the Colon and Rectum,2022,65(2):.271-275. [2] 沈峰,张飞宇,瞿春莹,等. 内镜下泡沫硬化剂注射联合橡皮圈套扎治疗Ⅱ~Ⅲ度内痔的前瞻性临床研究(含视频)[J]. 中华消化内镜杂志,2021,38(9):696-701. doi: 10.3760/cma.j.cn321463-20210622-00401 [3] 叶营,梁艳芳,孙相钊,等. 内镜下套扎术、透明帽辅助注射聚桂醇泡沫或原液硬化剂治疗内痔的对比研究[J]. 现代消化及介入诊疗,2022,27(2):185-189. doi: 10.3969/j.issn.1672-2159.2022.02.012 [4] 《结直肠肛门外科》杂志编辑委员会. 聚桂醇®内痔硬化注射疗法专家共识(2021版)[J]. 结直肠肛门外科,2021,27(3):183-187. [5] 徐柳,李胜保,金曙,等. 不同剂量聚桂醇泡沫硬化剂治疗出血性内痔的临床观察[J]. 临床消化病杂志,2022,34(3):207-208. [6] 李显芳,覃泳缤,黎振林,等. 内镜下聚桂醇泡沫硬化剂治疗内痔的疗效观察[J]. 微创医学,2020,15(2):242-243. [7] 艾武,努尔买买提·玉素英,阿力木江·阿布都热衣木. 聚桂醇泡沫硬化剂治疗痔病的临床效果分析[J]. 医药前沿,2021,11(20):28-30. [8] Liu T,Jun W,Xu-F D,et al. Evaluation of the clinical efficacy and safety of TST33 mega hemorrhoidectomy for severe prolapsed hemorrhoids[J]. World Journal of Clinical Cases,2022,10(18):6060-6068. [9] Elhefny A,Shoka A,Elghandour A,et al. A comparative study between stapled hemorrhoidopexy and laser hemorrhoidoplasty in the treatment of second-degree and third-degree hemorrhoids[J]. The Egyptian Journal of Surgery,2021,40(4):1046-1055. [10] 刘启学,卢精华,吴春艳,等. 血管栓塞与内镜联合聚桂醇治疗内痔出血的疗效比较[J]. 实用临床医药杂志,2022,26(2):104-107. doi: 10.7619/jcmp.20212857 [11] 刘礼剑,黄晓燕,韦金秀,等. 内镜下注射硬化剂聚桂醇治疗消化性溃疡出血的效果观察[J]. 广西医学,2021,43(19):2276-2278. [12] 张健涛,刘晨,罗长琴. 内镜下聚桂醇硬化对老年痔疮术后康复进程及肛门疼痛的影响[J]. 贵州医药,2020,44(7):1102-1103. doi: 10.3969/j.issn.1000-744X.2020.07.037 [13] 周世勇,艾飞,刘德武,等. TST术联合聚桂醇点状注射治疗混合痔合并直肠黏膜内脱垂临床观察[J]. 中国全科医学,2021,24(S2):76-79. [14] 徐林生,胡炳德,梁丁保,等. 内镜下负压套扎术和痔上黏膜环切术治疗Ⅱ/Ⅲ度内痔的疗效对比[J]. 现代消化及介入诊疗,2020,25(4):527-528,532. doi: 10.3969/j.issn.1672-2159.2020.04.026 [15] 陈颖,陈炜,方青青,等. 透明帽辅助内镜下注射聚桂醇泡沫硬化剂治疗13例出血性内痔的临床观察[J]. 上海医药,2020,41(9):17-22. doi: 10.3969/j.issn.1006-1533.2020.09.004 [16] 陈苏阳,蒋燕,焦胜,等. 内镜下套扎联合泡沫硬化剂注射治疗Ⅱ~Ⅲ度内痔的疗效及安全性分析[J]. 实用临床医药杂志,2021,25(22):121-125. doi: 10.7619/jcmp.20214123 [17] 杨义超,常媛媛,陈玉杰,等. 聚桂醇硬化与外科手术治疗痔病的短期疗效对比分析[J]. 临床外科杂志,2020,28(8):778-780. doi: 10.3969/j.issn.1005-6483.2020.08.025 [18] Caparelli M L,Batey J C,Tailor A,et al. Internal hemorrhoid harboring adenocarcinoma:A case report[J]. World Journal of Gastrointestinal Oncology,2021,13(1):87-91.